544445 — Asston Pharmaceuticals Income Statement
0.000.00%
- IN₹1.03bn
- IN₹1.10bn
- IN₹250.39m
- 32
- 24
- 70
- 35
Annual income statement for Asston Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | PROSPECTUS | PROSPECTUS | PROSPECTUS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 80.3 | 101 | 65.4 | 156 | 250 |
Cost of Revenue | |||||
Gross Profit | 27.3 | 34.3 | 31.9 | 58.3 | 109 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 78.8 | 99.5 | 48.4 | 128 | 189 |
Operating Profit | 1.5 | 1.85 | 16.9 | 27.5 | 61 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 1.21 | 1.53 | 14.1 | 18.2 | 57 |
Provision for Income Taxes | |||||
Net Income After Taxes | 0.916 | 1.12 | 10.6 | 13.6 | 43.3 |
Net Income Before Extraordinary Items | |||||
Net Income | 0.916 | 1.12 | 10.6 | 13.6 | 43.3 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 0.916 | 1.12 | 10.6 | 13.6 | 43.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.108 | 0.132 | 1.24 | 1.55 | 5.08 |